A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Inclusion Criteria:
Exclusion Criteria:
Exclusion criteria are defined in each ISA.
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Jacksonville, Florida 32256, United States
New York, New York 10065-6007, United States
New York, New York 10065-6007, United States
New York, New York 10065-6007, United States
Victoria, 3000, Australia
61893467600
Aichi-Ken, 4600001, Japan
81120023812
Cho-ku, 104-0045, Japan
81120023812
Miyagi-Ken, 9808574, Japan
81120023812
954-265-6549
941-377-9993
404-778-3708
60611-3013
617-632-5847
507-284-2511
402-559-5166
607-272-5414
516-734-8959
646-608-4273
646-608-4273
919-684-8111
614-293-3196
215-662-3933
615-524-4074
713-792-2860
98104-3588
414-805-4600
+61882044018
61396561158
+33240083271
+39512144042
+390226434797
81120023812
81120023812
81120023812
+48124003200
+48223496334
821071243234
+441132433144
+447728268414
+441752431043